1302 例单中心观察性肝细胞癌真实世界队列的流行病学特征与预后.

Objective To investigate the epidemiological characteristics and clinical prognosis of hepatocellular carcinoma (HCC). Methods 1302 HCC patients who were diagnosed and treated in Hepatology Center, Nanfang Hospital, from January 1, 2011 to October 31, 2017 were enrolled, and their clinical and follow-up data were recorded to analyze epidemiological characteristics, recurrence, and survival. The chi-square test was used for comparison of categorical variables, and the Kaplan-Meier method was used to calculate survival and recurrence rates, log-rank test was used for comparison. Results 1302 patients with a male/female ratio of 8.50:1 and a mean age of 52.46±11.51 years. Of all 1302 patients, 1163 (89.32%) had HBV infection, with a HBeAg-positive/HBeAg-negative ratio of 1:3.05; 32 (2.46%) had HCV infection, and 12 (0.92%) had HBV and HCV infections. Of all patients, 1012 (77.73%) had liver cirrhosis. As for liver function classification, most patients are had Child-Pugh class A-B and albumin-bilirubin grade 1-2 liver disease. As for Barcelona Clinic Liver Cancer (BCLC) stage, 76 patients (5.84%) had BCLC stage 0, 474 (36.41%) had stage A, 236 (18.13%) had stage B, 504 (38.71%) had stage C, and 12 (0.92%) had stage D HCC. Of all 1302 patients, 261 (20.05%) received radical treatment at baseline, and surgery was the main treatment method; among the remaining 1041 patients (79.95%), most of them received transarterial chemoembolization. The follow-up time ranged from 0.27 to 88.70 months, with a median follow-up time of 13.33 months. The 5-year median overall survival time of all patients was 21.53±1.59 months (95% confidence interval ［CI］: 18.411-24.656), and there was a significant difference in survival time between the patients with different BCLC stages (P<0.001). In the patients who received radical treatment, the 5-year median overall survival time was not obtained, and their 5-year median recurrence-free survival time was 40.90±4.81 months (95% CI: 31.467-50.333). Conclusion HCC has the epidemiological characteristics from the aspects of demography, etiology, tumor features, and treatment and prognosis, and there are still problems such as a low rate of identification in the early stage, a low rate of radical treatment, and a short survival time. Strategies for HCC prevention and treatment require further investigation and improvement. [ABSTRACT FROM AUTHOR]